Pfizer Identifies Synexus' South African Clinical Research Sites as INSPIRE Sites - First in Africa

Pfizer Identifies Synexus' South African Clinical Research Sites as INSPIRE 
Sites - First in Africa 
MANCHESTER, England, June 12, 2013 /CNW/ - Three of Synexus' South African 
dedicated clinical research centres Stanza, Watermeyer and Nyeleti have been 
identified by Pfizer as meeting the exacting standards that the company 
demands to join a worldwide network of INSPIRE sites which must be both highly 
productive and effective. 
INSPIRE, which stands for Investigator Networks, Site Partnerships and 
Infrastructure for Research Excellence, means that these sites have early 
access to Pfizer's portfolio data and advanced information regarding the 
clinical trials to be sponsored by Pfizer. They are also involved in 
publications in scientific journals, protocol design, advisory boards and the 
sharing of best practice across the INSPIRE network. 
Synexus, which is the world's largest multi-national company focused on the 
recruitment and running of clinical trials, already has an INSPIRE site in 
Wroclaw Poland. 
Tebogo Sebata, Investigator Site Development and Support Lead, Pfizer Global 
commented, "We are really delighted that we have been able to identify these 
sites and add them to our INSPIRE network. We put in place the INSPIRE 
programme so that we can work with the best sites across the world. Centres 
which have real expertise in the science of clinical trials, the 
infrastructure support that is necessary, proven recruitment strategies and 
the in depth knowledge can help us maximize our development programmes going 
forward." 
Dr Sanet Aspinall, Managing Director of Synexus South Africa, commented, "We 
are thrilled to have been invited to become part of the INSPIRE network. We 
have had to go through an exhaustive assessment programme which looked at our 
previous experience, expertise across a range of therapeutic areas, 
infrastructure and resources and effective recruitment strategies. This is not 
only excellent for our company but for South Africa as it shows that it is a 
very good place in which to carry out clinical trials." 
Dr Glynis Neagle, Chief Medical Officer for Synexus concluded, "We are really 
focussed on providing our clients with quality patients and data. To do this, 
we are training our doctors and clinical staff in the medical science of the 
therapy areas we focus on; cardiovascular, metabolic (diabetes and obesity), 
bone, respiratory, infectious diseases and CNS (dementia and pain). Our 
investigators are experts in clinical trials and apply this knowledge to each 
trial which gives added value to clients." 
Simon Vane Percy simon@vanepercy.com + 44-(0)1737-821-890 
SOURCE: SYNEXUS 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/June2013/12/c7453.html 
CO: SYNEXUS 
-0- Jun/12/2013 12:38 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.